Table 2.
Promising vaccines against ASFV developed in 2015–2021.
| ASFV Strain | Virulence | Genotype (P27) | Deleted Genes | Deletion Mutant | Effects | Reference |
|---|---|---|---|---|---|---|
| Georgia 2010 | II | I177L | ASFV-G-ΔI177L | full attenuation in pigs | [57] | |
| Georgia 2010 | II | I177L | ASFV-G-ΔI177L | Oronasal administration is as effective as i.m. administration, animals remained clinically healthy after challenge with ASFV-G, and the specific antibody response was on the same level | [58] | |
| HLJ/18 | High | II | Gene segments MGF505-1R, MGF505-2R, MGF505-3R, MGF360-12L, MGF360-13L, MGF360-14L | HLj/18-7GD | full attenuation in pigs, assurance of complete immunity against lethal ASFV challenge, unable to be converted to the virulent strain | [59] |
| OURT 88/3 | Low | I | I329L | OURT88/3ΔI329L | inhibits the host’s innate immune response, | [60] |
| L v17/WB/Rie1217 | II | 92% protection in wild boars after challenge with the virulent ASF virus isolate Arm07 | [61] | |||
| Georgia 2007 | High | II | 9GL (B119L) UK (DP96R) |
full attenuation in pigs | [62,63] |